PT  - JOURNAL ARTICLE
AU  - Globerson Levin, Anat
AU  - Rawet Slobodkin, Moran
AU  - Waks, Tova
AU  - Horn, Galit
AU  - Ninio-Many, Lihi
AU  - Deshet Unger, Naamit
AU  - Ohayon, Yaara
AU  - Suliman, Shimrit
AU  - Cohen, Yael
AU  - Tartakovsky, Boris
AU  - Naparstek, Ella
AU  - Avivi, Irit
AU  - Eshhar, Zelig
TI  - Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity
AID  - 10.1158/2326-6066.CIR-20-0118
DP  - 2020 Oct 02
TA  - Cancer Immunology Research
4099  - http://cancerimmunolres.aacrjournals.org/content/early/2020/11/05/2326-6066.CIR-20-0118.short
4100  - http://cancerimmunolres.aacrjournals.org/content/early/2020/11/05/2326-6066.CIR-20-0118.full
AB  - Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable successes in fighting B-cell leukemias/lymphomas. Promising response rates are reported in patients treated with B-cell maturation antigen (BCMA) CAR T cells for multiple myeloma. However, responses appear to be nondurable, highlighting the need to expand the repertoire of multiple myeloma–specific targets for immunotherapy and to generate new CAR T cells. Here, we developed a “dual-CAR” targeting two multiple myeloma–associated antigens and explored its safety and efficacy. To reduce the “off-target” toxicity, we used the recognition of paired antigens that were coexpressed by the tumor to induce efficient CAR T-cell activation. The dual-CAR construct presented here was carefully designed to target the multiple myeloma–associated antigens, taking into consideration the distribution of both antigens on normal human tissues. Our results showed that the CD138/CD38-targeted dual CAR (dCAR138-38) elicited a potent anti–multiple myeloma response both in vitro and in vivo. NSG mice transplanted with a multiple myeloma cell line and treated with dCAR138-38 showed median survival of 97 days compared with 31 days in the control group treated with mock-lymphocytes. The dCAR138-38 showed increased specificity toward cells expressing both targeted antigens compared with single-antigen–expressing cells and low activity toward primary cells from healthy tissues. Our findings indicated that the dCAR138-38 may provide a potent and safe alternative therapy for patients with multiple myeloma.